



OPEN ACCESS

EDITED AND REVIEWED BY
Michael J. Barratt,
Washington University in St. Louis,
United States

*CORRESPONDENCE
Ke Chen
✉ kechen@uestc.edu.cn

[†]These authors share first authorship

RECEIVED 08 July 2025
ACCEPTED 22 July 2025
PUBLISHED 04 August 2025

CITATION
Zhang X, Chen K, Lan H, Chen H, Chen H,
Yang P, He N, Hung W, Zeng Z and Liu C
(2025) Correction: Effect of *Bifidobacterium*
longum subsp. *infantis* YLGB-1496 on
common diseases in pediatrics: a randomized,
blinded, placebo-controlled trial.
Front. Nutr. 12:1661669.
doi: 10.3389/fnut.2025.1661669

COPYRIGHT
© 2025 Zhang, Chen, Lan, Chen, Chen, Yang,
He, Hung, Zeng and Liu. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution](#)
[License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Correction: Effect of *Bifidobacterium longum* subsp. *infantis* YLGB-1496 on common diseases in pediatrics: a randomized, blinded, placebo-controlled trial

Xi Zhang^{1†}, Ke Chen^{2*†}, Hanglian Lan^{3†}, Haixia Chen⁴, Hua Chen⁴,
Ping Yang⁵, Nianyang He⁵, Weilian Hung³, Zaozhong Zeng³ and
Changqi Liu⁶

¹Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, ²Department of Nutrition, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, ³National Center of Technology Innovation for Dairy, Hohhot, China, ⁴Baoxing Center for Disease Control and Prevention, Yaan, China, ⁵Department of Child Health Care, Xindu Maternal and Child Health Care Hospital, Chengdu, China, ⁶School of Exercise and Nutritional Sciences, San Diego State University, San Diego, CA, United States

KEYWORDS

probiotics, short chain fatty acids, children, gut microbiota, upper respiratory tract infection

A Correction on

Effect of *Bifidobacterium longum* subsp. *infantis* YLGB-1496 on common diseases in pediatrics: a randomized, blinded, placebo-controlled trial

by Zhang, X., Chen, K., Lan, H., Chen, H., Chen, H., Yang, P., He, N., Hung, W., Zeng, Z., and Liu, C. (2025). *Front. Nutr.* 12:1585504. doi: 10.3389/fnut.2025.1585504

In the published article, there was an error in [Table 2](#), “Comparison of the days of common symptoms in infants and young children during the intervention period” as published.

The positions of “IG” and “CG” in the column headings were erroneously swapped. Similarly, “44 0.89” and “99 2.2” in the “Fever” row were incorrectly switched.

The corrected [Table 2](#) appears below.

The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 2 Comparison of the days of common symptoms in infants and young children during the intervention period.

Common symptoms	CG (N = 50)		IG (N = 50)		p-value
	Total occurrence days	Incident rate per 100 intervention days (%) [†]	Total occurrence days	Incident rate per 100 intervention days (%) [†]	
Cough*	190	4.22	99	2.2	<0.001
Runny nose	171	3.8	136	3.02	0.133
Stuffy nose	120	2.67	83	1.84	0.066
Fever*	99	2.2	40	0.89	<0.001
Loose stools	97	2.16	120	2.67	0.413
Increased frequency of bowel movements	105	2.33	105	2.33	0.921
Colic of the intestines	105	2.33	102	2.27	0.979
Dry stool*	346	7.69	157	3.49	0.012
Choking	45	1	58	1.29	0.387
Increased belching/bloating/anal gas	87	1.93	89	1.98	0.915
Retching/vomiting	35	0.78	52	1.16	0.244
Stool with milk flaps/food residues/sour odor	183	4.07	194	4.31	0.867
Reflux	58	1.29	64	1.42	0.393
Decreased appetite	181	4.02	135	3	0.285
Dysphoria	225	5	151	3.36	0.659
Refusal to eat	83	1.84	145	3.22	0.065
Eczematous changes of the skin*	578	12.84	134	2.98	0.002
Erythematous changes in the skin	12	0.27	9	0.2	0.958
Skin wheal-like changes	10	0.22	7	0.16	0.552

[†] A total of 9,000 study days (calculated method: 180 days × 50 people). Symptom incidence per 100 intervention days = duration of a symptom/total intervention days × 100%.
*Mann–Whitney *U*-test for two independent samples, *p*-values <0.01. Dry stool refers to stool Bristol score type 1–3 stool.
IG, intervention group; CG, control group.